
Work Here?
Work Here?
Work Here?
Adaptyv Biosystems designs and sells custom proteins—such as antibodies and enzymes—produced using AI-guided design and cell-free synthetic biology. Its process uses automated workcells to express and test thousands of protein designs on demand, with experimental data feeding back into AI models to improve future designs. A forthcoming AI-enabled foundry will integrate sequencing design, experimental planning, autonomous execution, and data tracking across the protein-engineering cycle. The company aims to shorten development timelines and deliver protein designs that can prevent or treat disease, differentiating itself through end-to-end automation, cell-free expression, and iterative AI optimization.
Industries
Robotics & Automation
AI & Machine Learning
Biotechnology
Healthcare
Company Size
11-50
Company Stage
Series A
Total Funding
$8.5M
Headquarters
Lausanne, Switzerland
Founded
2020
Help us improve and share your feedback! Did you find this helpful?
Total Funding
$8.5M
Below
Industry Average
Funded Over
5 Rounds
Industry standards
Adaptyv Bio: an easier way to engineer proteins using an automated cloud labEpalinges-based Adaptyv Bio has taken protein engineering to a whole new level. Acting as a high-tech protein foundry, the start-up speeds up the design process for proteins. As of today, protein engineering remains a long, very tedious, and expensive task as labs and companies lack the automation and data integration to perform repeatable, scalable protein testing. This is where Adaptyv Bio works its magic: taking advantage of its automated wet lab the company builds a solution for rapid experimental validation of newly designed proteins, while also drastically reducing the costs per protein. Combined with artificial intelligence, this new technology will make it easier for protein designers to engineer new proteins for a variety of applications, such as designed antibodies, novel enzymes or alternative materials.The Tech Seed loan from FIT will enable Adaptyv to verify the commercial validity of its antibody screening platform and roll out access to the platform at the end of this year.Hexem produces biogas from wastewater cleaningHexem has developed a novel wastewater technology, which produces biogas from industrial waste streams. Its technology uses electrical currents in a bioreactor to clean up contaminated water and produce biogas out of it. Nowadays, cleaning industrial wastewater costs enormous amounts of money. Yet, wastewater is an untapped resource containing nutrients and energy alike. Full energy recovery would make wastewater treatment not only energy-neutral but also profitable. And that’s what Hexem enables.The startup’s main users are in the food and beverage industry such as dairies, breweries, wineries and other producers of high strength wastewater like biofuel refineries. With Hexem’s bioreactor installed, they will be able to significantly reduce their water treatment cost and produce clean energy, which can then be reused directly.In the upcoming months, Hexem will build an industrial demonstrator in its container workshop in Port-Valais, thanks to the FIT Tech Seed loan. After ensuring the technical feasibility, this demonstrator will be transferred to an industrial site in Valais.(Press release)
Adaptyv Biosystems, a Vaud-based start-up, has raised $8 million in seed funding to enhance its automated cloud lab for AI-powered protein validation. The funding round was led by ACE Ventures with participation from ByFounders, Founderful, LongGame Ventures, and individual investors. Adaptyv's platform automates the "design–test–learn" cycle, allowing researchers to validate AI-generated protein designs remotely, speeding up the experimental validation process.
Vaud-based startup Adaptyv, specializing in the experimental validation of ai-generated proteins, has raised CHF 6,40 million in seed funding.
Adaptyv Bio has officially launched its protein design platform after leaving the beta phase, following an $8 million seed round led by Ace Ventures. The platform, which uses AI to facilitate rapid protein testing and synthesis, has been adopted by over 30 companies, including major pharma firms and AI labs. The funding will help Adaptyv expand its team and infrastructure to meet growing demand.
EPFL Spinoff Adaptyv Bio is dedicated to closing the loop between computational prediction and experimental validation with cell-free synthetic biology and high-throughput nanofluidics. Its protein engineering platform is now available in the market.Identifying new antibodies is fundamental in fighting diseases such as viral infections, autoimmune diseases, and cancers. Unfortunately, the current process for testing the efficacy of new antibodies is slow and expensive and has a failure rate of around 88%. Combining robotics, microfluidics and synthetic biology techniques, Adaptyv Bio is building a full-stack platform – protein foundry – that allows protein engineers to design and test new proteins and generate data about their proteins in order to develop new medicines, better enzymes for research and industrial applications or functional materials with novel properties. To enable that tight feedback loop from computational design to experimental validation, Adaptyv is innovating on all levels of the technology stack: from custom synthetic biology techniques for designing DNA, synthesizing proteins and assaying them, to novel lab-on-chip modular work cells that can replace multiple commercial instruments at once, to advanced lab robotics that allow the company to run experiments autonomously. This will reduce reagent consumption, time per experiment and thus cost per data point generated by multiple orders of magnitude compared to today’s approaches
Find jobs on Simplify and start your career today
Industries
Robotics & Automation
AI & Machine Learning
Biotechnology
Healthcare
Company Size
11-50
Company Stage
Series A
Total Funding
$8.5M
Headquarters
Lausanne, Switzerland
Founded
2020
Find jobs on Simplify and start your career today